Why Insulet Corporation (NASDAQ:PODD) Looks Like A Quality Company
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of learni
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $240
Wells Fargo analyst Larry Biegelsen maintains $Insulet(PODD.US)$ with a buy rating, and maintains the target price at $240.According to TipRanks data, the analyst has a success rate of 58.6% and a tot
Form 144 | Insulet(PODD.US) Insider Proposes to Sell 4.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 25, $Insulet(PODD.US)$ Insider Petrovic Shacey intends to sell 20,000 shares of its common stock on Jun 25, with a total market value of approximately $4.07 million. Sou
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 -- Barrons.com
An automated insulin pump markedly improved the health of patients with Type 2 diabetes, the pump maker Insulet told a conference last weekend. The company is asking regulators to clear its Omnipod pump as the first automated dispenser for the 30 million Americans with the disorder.
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks
Tandem Diabetes, DexCom See Weakness Following ADA Conference
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $260
Jefferies analyst Matthew Taylor maintains $Insulet(PODD.US)$ with a buy rating, and maintains the target price at $260.According to TipRanks data, the analyst has a success rate of 60.9% and a total
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
TD Cowen analyst Josh Jennings maintains $Insulet(PODD.US)$ with a buy rating, and maintains the target price at $264.According to TipRanks data, the analyst has a success rate of 51.0% and a total av
Insulet Plans Label Expansion for Omnipod in Type 2 Diabetes
BofA Securities Maintains Insulet(PODD.US) With Buy Rating, Announces Target Price $255
BofA Securities analyst Travis Steed maintains $Insulet(PODD.US)$ with a buy rating, and sets the target price at $255.According to TipRanks data, the analyst has a success rate of 63.3% and a total a
Reported Earlier, Insulet's Omnipod 5 System Proves Effective in Type 2 Diabetes Management
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today shared positive results from its Omnipod 5 A
Express News | Insulet’s Secure-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
Express News | Insulet Corp - GLP-1 Initiation Does Not Impact the Continued Use of Insulin Among Current Insulin Users
Express News | Insulet Corp - More Than Half (55%) of People Who Adopt GLP-1 Therapy Discontinue Treatment Within 12 Months
Express News | Insulet Corp - Patients Who Stop GLP-1 Therapy Within the First 3 Months Are Even More Likely to Initiate Insulin Than Those Who Continue
Express News | Insulet Corp:Partnered With Optum Health Economics & Outcomes Research to Conduct Real-World Analysis Using Broad & Representative U.S. Claims Dataset
Express News | Insulet Corp - Patients Who Adopt GLP-1 Therapy Are Twice as Likely to Also Initiate Insulin Therapy Within the Ensuing 12 Months